Related Experiment Video
Updated: Oct 7, 2025
06:04
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
1.1K
IS THE WAIST/HEIGHT RATIO A BETTER PARAMETER THAN BMI IN DETERMINING THE CARDIOMETABOLIC RISK PROFILE OF OBESE
Andressa Bressan Malafaia1, Paulo Afonso Nunes Nassif1,2,3, Ricardo Wallace das Chagas Lucas3
1Mackenzie Evangelical Faculty of Paraná, Curitiba, PR, Brazil.
Summary
Roux-en-Y gastric bypass significantly improves metabolic syndrome markers. Waist-to-height ratio is a better indicator of cardiometabolic risk than BMI post-surgery.
Area of Science:
- Metabolic Surgery
- Cardiovascular Disease Prevention
- Obesity Management
Background:
- Rising obesity rates drive metabolic syndrome and cardiovascular disease risks.
- Metabolic syndrome components include hyperglycemia, dyslipidemia, and hypertension.
- Bariatric surgery is recognized for managing individual metabolic syndrome factors.
Purpose of the Study:
- To assess Roux-en-Y gastric bypass impact on metabolic syndrome.
- Compare pre- and postoperative laboratory results.
- Evaluate waist/height ratio and BMI for cardiometabolic risk.
Main Methods:
- Retrospective study of 80 Roux-en-Y gastric bypass patients.
- Analyzed BMI, waist circumference, waist/height ratio, lipids, glucose, HbA1c, insulin.
- Data collected preoperatively and 1-6 months, and 1-2 years postoperatively.
Main Results:
- Significant improvements observed in all clinical parameters.
- Mean BMI decreased from 39.8 to 26 by 1 year post-surgery.
- Waist circumference and waist/height ratio showed substantial reductions.
Conclusions:
- Roux-en-Y gastric bypass effectively improves metabolic syndrome.
- Waist-to-height ratio surpasses BMI for assessing cardiometabolic risk post-surgery.
More Related Videos
09:36Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
27.3K
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
14.3K
Related Concept Videos
01:24Obesity
671
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
671
01:21Drug Dosing: Obese Patients
8
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
8
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
6
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
6
01:29Cholesterol: Significance and Regulation
731
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
731
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
5
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
5
01:12Hazard Ratio
284
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
284